September 6, 2018 04:37 PM EDT

Zealand hands off disappointing diabetes revenue from Sanofi in exchange for a $205M injection to back a new pipeline

John Carroll

Editor & Founder

Danish biotech Zealand Pharma is cashing in its royalty chips on its lackluster diabetes drugs. The company, which has switched focus to its rare disease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Zealand hands off disappointing diabetes revenue from Sanofi in exchange for a $205M injection to back a new pipeline

John Carroll

Editor & Founder

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Exclusive: Florida cancer biotech raises $100M Series A

Sofinnova outlines $550M fund after IPOs and M&A deals

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Zealand hands off dis­ap­point­ing di­a­betes rev­enue from Sanofi in ex­change for a $205M in­jec­tion to back a new pipeline

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Zealand hands off disappointing diabetes revenue from Sanofi in exchange for a $205M injection to back a new pipeline

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Exclusive: Florida cancer biotech raises $100M Series A

Sofinnova outlines $550M fund after IPOs and M&A deals

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.